Cargando…

Genomic features of rapid versus late relapse in triple negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct clinical and genomic features...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiqing, Asad, Sarah, Weber, Zachary, Tallman, David, Nock, William, Wyse, Meghan, Bey, Jerome F., Dean, Kristin L., Adams, Elizabeth J., Stockard, Sinclair, Singh, Jasneet, Winer, Eric P., Lin, Nancy U., Jiang, Yi-Zhou, Ma, Ding, Wang, Peng, Shi, Leming, Huang, Wei, Shao, Zhi-Ming, Cherian, Mathew, Lustberg, Maryam B., Ramaswamy, Bhuvaneswari, Sardesai, Sagar, VanDeusen, Jeffrey, Williams, Nicole, Wesolowski, Robert, Obeng-Gyasi, Samilia, Sizemore, Gina M., Sizemore, Steven T., Verschraegen, Claire, Stover, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130400/
https://www.ncbi.nlm.nih.gov/pubmed/34006255
http://dx.doi.org/10.1186/s12885-021-08320-7
_version_ 1783694518800875520
author Zhang, Yiqing
Asad, Sarah
Weber, Zachary
Tallman, David
Nock, William
Wyse, Meghan
Bey, Jerome F.
Dean, Kristin L.
Adams, Elizabeth J.
Stockard, Sinclair
Singh, Jasneet
Winer, Eric P.
Lin, Nancy U.
Jiang, Yi-Zhou
Ma, Ding
Wang, Peng
Shi, Leming
Huang, Wei
Shao, Zhi-Ming
Cherian, Mathew
Lustberg, Maryam B.
Ramaswamy, Bhuvaneswari
Sardesai, Sagar
VanDeusen, Jeffrey
Williams, Nicole
Wesolowski, Robert
Obeng-Gyasi, Samilia
Sizemore, Gina M.
Sizemore, Steven T.
Verschraegen, Claire
Stover, Daniel G.
author_facet Zhang, Yiqing
Asad, Sarah
Weber, Zachary
Tallman, David
Nock, William
Wyse, Meghan
Bey, Jerome F.
Dean, Kristin L.
Adams, Elizabeth J.
Stockard, Sinclair
Singh, Jasneet
Winer, Eric P.
Lin, Nancy U.
Jiang, Yi-Zhou
Ma, Ding
Wang, Peng
Shi, Leming
Huang, Wei
Shao, Zhi-Ming
Cherian, Mathew
Lustberg, Maryam B.
Ramaswamy, Bhuvaneswari
Sardesai, Sagar
VanDeusen, Jeffrey
Williams, Nicole
Wesolowski, Robert
Obeng-Gyasi, Samilia
Sizemore, Gina M.
Sizemore, Steven T.
Verschraegen, Claire
Stover, Daniel G.
author_sort Zhang, Yiqing
collection PubMed
description BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct clinical and genomic features of primary tumors. METHODS: Using three publicly-available datasets, we identified 453 patients diagnosed with primary TNBC with adequate follow-up to be characterized as ‘rapid relapse’ (rrTNBC; distant relapse or death ≤2 years of diagnosis), ‘late relapse’ (lrTNBC; > 2 years) or ‘no relapse’ (nrTNBC: > 5 years no relapse/death). We explored basic clinical and primary tumor multi-omic data, including whole transcriptome (n = 453), and whole genome copy number and mutation data for 171 cancer-related genes (n = 317). Association of rapid relapse with clinical and genomic features were assessed using Pearson chi-squared tests, t-tests, ANOVA, and Fisher exact tests. We evaluated logistic regression models of clinical features with subtype versus two models that integrated significant genomic features. RESULTS: Relative to nrTNBC, both rrTNBC and lrTNBC had significantly lower immune signatures and immune signatures were highly correlated to anti-tumor CD8 T-cell, M1 macrophage, and gamma-delta T-cell CIBERSORT inferred immune subsets. Intriguingly, lrTNBCs were enriched for luminal signatures. There was no difference in tumor mutation burden or percent genome altered across groups. Logistic regression mModels that incorporate genomic features significantly outperformed standard clinical/subtype models in training (n = 63 patients), testing (n = 63) and independent validation (n = 34) cohorts, although performance of all models were overall modest. CONCLUSIONS: We identify clinical and genomic features associated with rapid relapse TNBC for further study of this aggressive TNBC subset. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08320-7.
format Online
Article
Text
id pubmed-8130400
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81304002021-05-19 Genomic features of rapid versus late relapse in triple negative breast cancer Zhang, Yiqing Asad, Sarah Weber, Zachary Tallman, David Nock, William Wyse, Meghan Bey, Jerome F. Dean, Kristin L. Adams, Elizabeth J. Stockard, Sinclair Singh, Jasneet Winer, Eric P. Lin, Nancy U. Jiang, Yi-Zhou Ma, Ding Wang, Peng Shi, Leming Huang, Wei Shao, Zhi-Ming Cherian, Mathew Lustberg, Maryam B. Ramaswamy, Bhuvaneswari Sardesai, Sagar VanDeusen, Jeffrey Williams, Nicole Wesolowski, Robert Obeng-Gyasi, Samilia Sizemore, Gina M. Sizemore, Steven T. Verschraegen, Claire Stover, Daniel G. BMC Cancer Research BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct clinical and genomic features of primary tumors. METHODS: Using three publicly-available datasets, we identified 453 patients diagnosed with primary TNBC with adequate follow-up to be characterized as ‘rapid relapse’ (rrTNBC; distant relapse or death ≤2 years of diagnosis), ‘late relapse’ (lrTNBC; > 2 years) or ‘no relapse’ (nrTNBC: > 5 years no relapse/death). We explored basic clinical and primary tumor multi-omic data, including whole transcriptome (n = 453), and whole genome copy number and mutation data for 171 cancer-related genes (n = 317). Association of rapid relapse with clinical and genomic features were assessed using Pearson chi-squared tests, t-tests, ANOVA, and Fisher exact tests. We evaluated logistic regression models of clinical features with subtype versus two models that integrated significant genomic features. RESULTS: Relative to nrTNBC, both rrTNBC and lrTNBC had significantly lower immune signatures and immune signatures were highly correlated to anti-tumor CD8 T-cell, M1 macrophage, and gamma-delta T-cell CIBERSORT inferred immune subsets. Intriguingly, lrTNBCs were enriched for luminal signatures. There was no difference in tumor mutation burden or percent genome altered across groups. Logistic regression mModels that incorporate genomic features significantly outperformed standard clinical/subtype models in training (n = 63 patients), testing (n = 63) and independent validation (n = 34) cohorts, although performance of all models were overall modest. CONCLUSIONS: We identify clinical and genomic features associated with rapid relapse TNBC for further study of this aggressive TNBC subset. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08320-7. BioMed Central 2021-05-18 /pmc/articles/PMC8130400/ /pubmed/34006255 http://dx.doi.org/10.1186/s12885-021-08320-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Yiqing
Asad, Sarah
Weber, Zachary
Tallman, David
Nock, William
Wyse, Meghan
Bey, Jerome F.
Dean, Kristin L.
Adams, Elizabeth J.
Stockard, Sinclair
Singh, Jasneet
Winer, Eric P.
Lin, Nancy U.
Jiang, Yi-Zhou
Ma, Ding
Wang, Peng
Shi, Leming
Huang, Wei
Shao, Zhi-Ming
Cherian, Mathew
Lustberg, Maryam B.
Ramaswamy, Bhuvaneswari
Sardesai, Sagar
VanDeusen, Jeffrey
Williams, Nicole
Wesolowski, Robert
Obeng-Gyasi, Samilia
Sizemore, Gina M.
Sizemore, Steven T.
Verschraegen, Claire
Stover, Daniel G.
Genomic features of rapid versus late relapse in triple negative breast cancer
title Genomic features of rapid versus late relapse in triple negative breast cancer
title_full Genomic features of rapid versus late relapse in triple negative breast cancer
title_fullStr Genomic features of rapid versus late relapse in triple negative breast cancer
title_full_unstemmed Genomic features of rapid versus late relapse in triple negative breast cancer
title_short Genomic features of rapid versus late relapse in triple negative breast cancer
title_sort genomic features of rapid versus late relapse in triple negative breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130400/
https://www.ncbi.nlm.nih.gov/pubmed/34006255
http://dx.doi.org/10.1186/s12885-021-08320-7
work_keys_str_mv AT zhangyiqing genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT asadsarah genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT weberzachary genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT tallmandavid genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT nockwilliam genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT wysemeghan genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT beyjeromef genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT deankristinl genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT adamselizabethj genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT stockardsinclair genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT singhjasneet genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT winerericp genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT linnancyu genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT jiangyizhou genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT mading genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT wangpeng genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT shileming genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT huangwei genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT shaozhiming genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT cherianmathew genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT lustbergmaryamb genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT ramaswamybhuvaneswari genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT sardesaisagar genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT vandeusenjeffrey genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT williamsnicole genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT wesolowskirobert genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT obenggyasisamilia genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT sizemoreginam genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT sizemorestevent genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT verschraegenclaire genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer
AT stoverdanielg genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer